Charles Craddock and David Sallman discuss transplantation and immunotherapies in AML, focusing on patient eligibility, challenges in CAR-T therapy, targeting pre-transplant minimal residual disease, and improving patient outcomes through DLI and gamma delta T cells. They also explore the design of a randomized study evaluating prophylactic DLI in high-risk AML patients.

Charles Craddock and Christopher Hourigan discuss the important role of transplantation in AML, the value of pre-transplant MRD, and the management approaches for high-risk patients. They also explore strategies to improve outcomes for older AML patients through conditioning regimens and the introduction of cellular or drug therapies.

Experts Charles Craddock, Shernan Holtan, and Anna Sureda discuss GvHD and other post-transplant complications. They highlight the importance of addressing these complications and explore approaches to GvHD prophylaxis and treatment including regenerative medicine and different drug strategies.